CASI Pharma (NASDAQ: CASI) reported Q2 EPS of ($0.05), $0.02 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $7.16 million versus the consensus estimate of $6.02 million.

• Revenue Growth Guidance in 2021 Revised to Exceed 80% Over 2020

For earnings history and earnings-related data on CASI Pharma (CASI) click here.